Literature DB >> 25602681

Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Mohamed Abdel-Mohsen1, Charlene Wang, Matthew C Strain, Steven M Lada, Xutao Deng, Leslie R Cockerham, Christopher D Pilcher, Frederick M Hecht, Teri Liegler, Douglas D Richman, Steven G Deeks, Satish K Pillai.   

Abstract

OBJECTIVE: The eradication of HIV necessitates elimination of the HIV latent reservoir. Identifying host determinants governing latency and reservoir size in the setting of antiretroviral therapy (ART) is an important step in developing strategies to cure HIV infection. We sought to determine the impact of cell-intrinsic immunity on the HIV latent reservoir.
DESIGN: We investigated the relevance of a comprehensive panel of established anti-HIV-1 host restriction factors to multiple established virologic and immunologic measures of viral persistence in HIV-1-infected, ART-suppressed individuals.
METHODS: We measured the mRNA expression of 42 anti-HIV-1 host restriction factors, levels of cell-associated HIV-1 RNA, levels of total pol and 2-long terminal repeat (2-LTR) circle HIV-1 DNA and immunophenotypes of CD4 T cells in 72 HIV-1-infected individuals on suppressive ART (23 individuals initiated ART less than 1 year post-infection, and 49 individuals initiated ART greater than 1 year post-infection). Correlations were analysed using nonparametric tests.
RESULTS: The enhanced expression of a few select host restriction factors, p21, schlafen 11 and PAF1, was strongly associated with reduced CD4 T-cell associated HIV RNA during ART (P < 0.001). In addition, our data suggested that ART perturbs the regulatory relationship between CD4 T-cell activation and restriction factor expression. Lastly, cell-intrinsic immune responses were significantly enhanced in individuals who initiated ART during early versus chronic infection and may contribute to the reduced reservoir size observed in these individuals.
CONCLUSION: Intrinsic immune responses modulate HIV persistence during suppressive ART and may be manipulated to enhance the efficacy of ART and promote viral eradication through reversal of latency in vivo.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25602681      PMCID: PMC4385712          DOI: 10.1097/QAD.0000000000000572

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  61 in total

1.  Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Authors:  Satish K Pillai; Mohamed Abdel-Mohsen; John Guatelli; Mark Skasko; Alexander Monto; Katsuya Fujimoto; Steven Yukl; Warner C Greene; Helen Kovari; Andri Rauch; Jacques Fellay; Manuel Battegay; Bernard Hirschel; Andrea Witteck; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard; Joseph K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

4.  Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.

Authors:  Irene Guendel; Emmanuel T Agbottah; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-03-24       Impact factor: 2.250

5.  APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.

Authors:  Qin Yu; Darlene Chen; Renate König; Roberto Mariani; Derya Unutmaz; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2004-10-04       Impact factor: 5.157

6.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

7.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

8.  A whole genome screen for HIV restriction factors.

Authors:  Li Liu; Nidia M M Oliveira; Kelly M Cheney; Corinna Pade; Hanna Dreja; Ann-Marie H Bergin; Viola Borgdorff; David H Beach; Cleo L Bishop; Matthias T Dittmar; Aine McKnight
Journal:  Retrovirology       Date:  2011-11-14       Impact factor: 4.602

9.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

10.  Expression profile of host restriction factors in HIV-1 elite controllers.

Authors:  Mohamed Abdel-Mohsen; Rui André Saraiva Raposo; Xutao Deng; Manqing Li; Teri Liegler; Elizabeth Sinclair; Mohamed S Salama; Hussam El-Din A Ghanem; Rebecca Hoh; Joseph K Wong; Michael David; Douglas F Nixon; Steven G Deeks; Satish K Pillai
Journal:  Retrovirology       Date:  2013-10-16       Impact factor: 4.602

View more
  24 in total

1.  Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Authors:  Nadejda Beliakova-Bethell; Amey Mukim; Cory H White; Savitha Deshmukh; Hosiana Abewe; Douglas D Richman; Celsa A Spina
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

2.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

Review 3.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

4.  Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy.

Authors:  Nathaniel D Bachtel; Greta A Beckerle; Talia M Mota; Miguel de Mulder Rougvie; Rui André Saraiva Raposo; R Brad Jones; Douglas F Nixon; Richard Apps
Journal:  AIDS Res Hum Retroviruses       Date:  2018-10-16       Impact factor: 2.205

Review 5.  The Importance of Human Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals.

Authors:  Sara Gianella; J Sonya Haw; Jill Blumenthal; Brooke Sullivan; Davey Smith
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

Review 6.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

7.  Schlafen 4-expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia.

Authors:  Lin Ding; Michael M Hayes; Amanda Photenhauer; Kathryn A Eaton; Qian Li; Ramon Ocadiz-Ruiz; Juanita L Merchant
Journal:  J Clin Invest       Date:  2016-07-18       Impact factor: 14.808

8.  Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.

Authors:  Surya Kumari Vadrevu; Irena Trbojevic-Akmacic; Andrew V Kossenkov; Florent Colomb; Leila B Giron; Alitzel Anzurez; Kenneth Lynn; Karam Mounzer; Alan L Landay; Robert C Kaplan; Emmanouil Papasavvas; Luis J Montaner; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  J Leukoc Biol       Date:  2018-04-06       Impact factor: 4.962

9.  HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.

Authors:  Sheila M Keating; Christopher D Pilcher; Vivek Jain; Mila Lebedeva; Dylan Hampton; Mohamed Abdel-Mohsen; Xutao Deng; Gary Murphy; Alex Welte; Shelley N Facente; Frederick Hecht; Steven G Deeks; Satish K Pillai; Michael P Busch
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

Review 10.  Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

Authors:  Mohamed Abdel-Mohsen; Douglas Richman; Robert F Siliciano; Michel C Nussenzweig; Bonnie J Howell; Javier Martinez-Picado; Nicolas Chomont; Katharine J Bar; Xu G Yu; Mathias Lichterfeld; Jose Alcami; Daria Hazuda; Frederic Bushman; Janet D Siliciano; Michael R Betts; Adam M Spivak; Vicente Planelles; Beatrice H Hahn; Davey M Smith; Ya-Chi Ho; Maria J Buzon; Christian Gaebler; Mirko Paiardini; Qingsheng Li; Jacob D Estes; Thomas J Hope; Jay Kostman; Karam Mounzer; Marina Caskey; Lawrence Fox; Ian Frank; James L Riley; Pablo Tebas; Luis J Montaner
Journal:  Nat Med       Date:  2020-09-07       Impact factor: 87.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.